ACS Medicinal Chemistry Letters
Letter
Manuel Elepano − Institute for Neurodegenerative Diseases
(IND), UCSF Weill Institute for Neurosciences, University of
California, San Francisco, San Francisco, California 94518,
United States
Makoto Hirasawa − R&D Division, Daiichi Sankyo Co., Ltd.,
Tokyo 140-8710, Japan
Masakazu Hirouchi − R&D Division, Daiichi Sankyo Co., Ltd.,
Tokyo 140-8710, Japan
Ryo Murakami − R&D Division, Daiichi Sankyo Co., Ltd.,
Tokyo 140-8710, Japan
Joanne Lee − Institute for Neurodegenerative Diseases (IND),
UCSF Weill Institute for Neurosciences, University of California,
San Francisco, San Francisco, California 94518, United States
Koji Sasaki − R&D Division, Daiichi Sankyo Co., Ltd., Tokyo
140-8710, Japan
Shimpei Hirano − R&D Division, Daiichi Sankyo Co., Ltd.,
Tokyo 140-8710, Japan
Takao Ohyama − R&D Division, Daiichi Sankyo Co., Ltd.,
Tokyo 140-8710, Japan
Benjamin C. Tang − Institute for Neurodegenerative Diseases
(IND), UCSF Weill Institute for Neurosciences, University of
California, San Francisco, San Francisco, California 94518,
United States
Roy J. Vaz − Institute for Neurodegenerative Diseases (IND),
UCSF Weill Institute for Neurosciences, University of California,
San Francisco, San Francisco, California 94518, United States
Masahiro Inoue − R&D Division, Daiichi Sankyo Co., Ltd.,
Tokyo 140-8710, Japan
Steven H. Olson − Institute for Neurodegenerative Diseases
(IND), UCSF Weill Institute for Neurosciences, University of
California, San Francisco, San Francisco, California 94518,
United States
pharmacokinetics; PSA, polar surface area; SAR, structure
activity relationship; YFP, yellow fluorescent protein
REFERENCES
■
2015, 349, 1255555.
̈
(2) Aoyagi, A.; Condello, C.; Stohr, J.; Yue, W.; Lee, J. C.; Rivera, B.
M.; Woerman, A. L.; Halliday, G.; van Duinen, S.; Ingelsson, M.;
Lannfelt, L.; Graff, C.; Bird, T. D.; Keene, C. D.; Seeley, W. W.;
Transl. Med. 2019, 11, 8462.
(4) Woerman, A. L.; Aoyagi, A.; Patel, S.; Kazmi, S. A.; Lobach, I.;
Grinberg, L. T.; McKee, W. W.; Olson, S. H.; Prusiner, S. B. Tau
S. A. 2016, 113, E8187−E8196.
(5) Sanders, D. W.; Kaufman, S. K.; DeVos, S. L.; Sharma, A. M.;
Mirbaha, H.; Barker, S. J.; Foley, A.; Thorpe, J. R.; Serpell, L. C.;
Miller, T. M.; Grinberg, L. T.; Seeley, W. W.; Diamond, M. I. Distinct
(6) Allen, B.; Ingram, E.; Takao, M.; Smith, M. J.; Jakes, R.; Virdee,
K.; Yoshida, H.; Holzer, M.; Craxton, M.; Emson, P. C.; Atzori, C.;
Migheli, A.; Crowther, R. A.; Ghetti, B.; Spillantini, M. G.; Goedert,
2002, 22, 9340−9351.
2584−2608.
(8) Wager, T. T.; Xinjun, H.; Verhoest, P. R.; Villalobos, A. Moving
449.
Stanley B. Prusiner − Institute for Neurodegenerative Diseases
(IND), UCSF Weill Institute for Neurosciences, University of
California, San Francisco, San Francisco, California 94518,
United States
(9) Wager, T. T.; Xinjun, H.; Verhoest, P. R.; Villalobos, A. Central
(10) Abraham, M. H.; Duce, P. P.; Prior, D. V.; Barratt, D. G.;
Soc., Perkin Trans. 2 1989, 6, 699−711.
Nick A. Paras − Institute for Neurodegenerative Diseases (IND),
UCSF Weill Institute for Neurosciences, University of California,
San Francisco, San Francisco, California 94518, United States;
Complete contact information is available at:
(11) Conformational searching was performed using Maestro
version 12 available from Schrodinger, LLC, New York, USA.
(12) Pierce, A. C.; ter Haar, E.; Binch, H. M.; Kay, D. P.; Patel, S. R.;
Li, P. CH···O and CH···N Hydrogen Bonds in Ligand Design: A Novel
Chem. 2005, 48, 1278−1281.
(14) opnMe (Boehringer Ingelheim). CDK8 Inhibitor BI-1347.
2019).
(15) Engelhardt, H.; Arnhof, H.; Carotta, S.; Hofmann, M. H.;
Kerenyi, M.; Scharn, D.. New Phenylpyrazolylacetamide Compounds
and Derivatives as CDK8/CDK19 Inhibitors. WO2017202719A1,
2017.
(16) Xi, M.; Chen, T.; Wu, C.; Gao, X.; Wu, Y.; Luo, X.; Du, K.; Yu,
Eur. J. Med. Chem. 2019, 164, 77−91.
Funding
This work was supported by a grant from the National
Institutes of Health (AG002132) (S.B.P.), as well as by
support from the Brockman Foundation (S.B.P.) and the
Sherman Fairchild Foundation (S.B.P.).
Notes
The authors declare the following competing financial
interest(s): The Institute for Neurodegenerative Diseases has
a research collaboration with Daiichi Sankyo (Tokyo, Japan).
Stanley B. Prusiner is a member of the Scientific Advisory
Board of ViewPoint Therapeutics and a member of the Board
of Directors of Trizell, Ltd., neither of which have contributed
financial or any other support to these studies.
ABBREVIATIONS
■
(17) Mallinger, A.; Schiemann, K.; Rink, C.; Sejberg, J.; Honey, M.
A.; Czodrowski, P.; Stubbs, M.; Poeschke, O.; Michael, B.; Schneider,
R.; Schwarz, D.; Musil, D.; Burke, R.; Urbahns, K.; Wienke, D.;
Clarke, P. A.; Raynaud, F. I.; Eccles, S. A.; Rohdich, F.; Blagg, J. 2.8-
BBB, blood brain barrier; ER, efflux ratio; CNS MPO, central
nervous system multiparameter optimization; HEK, human
embryonic kidney; LLCPK, pig kidney cell line; PK,
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX